In November, 2020, Zokinvy (lonafarnib) from Eiger BioPharmaceuticals became the first drug to win FDA approval to lower the risk of death resulting from Hutchinson-Gilford progeria syndrome, a progressive genetic disorder that leads to rapid aging in children. The FDA indication also covered the treatment of some processing-deficient progeroid laminopathies in patients one year of age…